Background In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1)
expression on≥ 50% of tumor cells, first-line treatment with the PD-1 inhibitor …

Background Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved
biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but …

KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor
subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL)–mutant lung …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …

Lung cancer causes the largest number of cancer-related deaths in the world. Most (85%) of
lung cancers are classified as non-small-cell lung cancer (NSCLC) and small-cell lung …

Immune checkpoint inhibitors against PD-1/PD-L1 yield improved survival rates of KRAS-
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …

Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …

Concurrent loss-of-function mutations in STK11 and KEAP1 in lung adenocarcinoma
(LUAD) are associated with aggressive tumor growth, resistance to available therapies, and …